

RESEARCH ARTICLE

Risk Factors for Invasive Fungal Infection among Thai Oncologic Patients with Febrile Neutropenia and Cutaneous Presentation: A 5-Year Retrospective Study in Southern Thailand

Kumpol Aiempanakit^{1*}, Surarit Naorungroj¹, Kanokphorn Chiratikarnwong¹, Sauvarat Auepemkiate², Benjawan Apinatriyo³

Abstract

Background: Febrile neutropenia (FNP) is a condition defined by fever and neutropenia. There are current only limited data on related cutaneous manifestations. This study aimed to assess cutaneous lesions and their etiologies in a Thai group of FNP patients. **Methods:** A retrospective analysis was conducted on 43 non-transplant febrile neutropenic patients with concurrent cutaneous lesions, as determined by dermatopathologic studies at Songklanagarind Hospital in Thailand over a five-year period. **Results:** The mean age was 39 years (SD: 18.8). Approximately 60% were male. The most common underlying disease was a hematologic neoplasm. Twenty-one of the participants had developed FNP within 7.5±8.7 days after presenting with skin lesions. Twenty-two participants had skin lesions 9.0±11.1 days after FNP diagnosis. Cutaneous manifestations were mostly in the form of multiple lesions (67.4%), of which the most common were nodular skin lesions (37.2%) presenting on the lower extremities of the body (58.1%). The dermatopathologic diagnoses included infections which were almost all fungal and leukemia cutis. The development of skin lesions after FNP proved to be a statistically significant risk factor for fungal infection (OR 8.13, P = 0.009), whereas age (over 40 years) proved to be a statistically significant protective factor (OR 0.20, P = 0.04). **Conclusions:** There are a variety of cutaneous manifestations in FNP, of which the most common were cutaneous nodular skin lesions in the lower extremities. The most frequent infection was fungal in patients under 40 who had developed skin lesions after FNP.

Keywords: Febrile neutropenia- cutaneous- fungal infection- hematologic malignancy- Thailand

Asian Pac J Cancer Prev, **18** (12), 3239-3243

Introduction

Febrile neutropenia (FNP) is a common condition in cancer patients who have been treated with chemotherapy. Infections, particularly those caused by bacterial pathogens, are the major cause of FNP related deaths. During the chemotherapy treatment period, a diagnosis of infection is often hampered, as the immunologic response can retard and mask symptoms.

According to recent Asian study, FNP had an incident rate in 14.9% or 24.8 per 1,000 cycles of chemotherapy per year (Limvorapitak and Khawcharoenporn, 2015). Approximately 6-15 percent of infections are located in the skin and soft tissue (Jagarlamudi et al., 2000; Roongpoovapart and Suankratay, 2010; Karanwal et al., 2013). In addition to infection, cutaneous lesions which include leukemia cutis, Sweet's syndrome, cutaneous vasculitis, acute graft versus host disease and cutaneous

drug eruptions, are symptoms during FNP (Bodey, 1994; Mays and Cohen, 2006; Farmakiotis et al., 2013; Llamas-Velasco et al., 2013). The purpose of this study was to describe the etiologies of dermatologic manifestations in febrile neutropenic patients and to assess factors associated with common causes of FNP. The final aim was to compare diagnostic yield between tissue biopsy for dermatopathologic and mycological studies.

Materials and Methods

Study Design

A comprehensive review of the electronic medical records of all patients with FNP who were diagnosed at the Songklanagarind Hospital Medical School in Southern Thailand between November 2009 and October 2014 was completed. Inclusion criteria were patients who (1) were diagnosed FNP in accordance with the 2010 Guidelines

¹Division of Dermatology, Department of Internal Medicine, ²Department of Pathology, Faculty of Medicine, Prince of Songkla University, ³Hematology Unit, Bangkok Hospital Hatyai, Hatyai, Songkhla, Thailand. *For Correspondence: akumpol@medicine.psu.ac.th

of the Infectious Diseases Society of America (IDSA) that specified that patients must have a fever and neutropenia; (2) had developed skin lesions and had undergone a histopathologic study during the FNP period. According to the IDSA, fever is defined as a single oral temperature of ≥ 38.3 °C or a temperature of ≥ 38.0 °C sustained over a one-hour period. Neutropenia is defined as an absolute neutrophil count (ANC) of < 500 cells/cu.mm or an ANC that is expected to decrease to < 500 cells/cu.mm within 48 hours (Freifeld et al., 2011). Patients with transplants were excluded. Patient data including information on age, gender, underlying diseases, chemotherapy regimen, and prescribed antibiotics were collected. Additionally, data pertaining to FNP, skin lesions, dermatopathologic diagnoses, and skin culture reports were collected. The patients with anticipated prolonged (> 7 days duration), profound neutropenia (ANC ≤ 100 cells/cu.mm) and/or significant medical co-morbid conditions, were categorized as high risk for FNP. Patients with few or no co-morbidities and brief neutropenic periods were categorized as low risk (Freifeld et al., 2011).

The study was approved by the Research Ethics Committee, Faculty of Medicine, Prince of Songkla University in accordance with the Declaration of Helsinki (REC 57-326-14-4). All patients were written informed consent before dermatopathologic studies.

Statistical Analysis

All statistical analyses were performed using the epicalc package (version 2.15.1.0) in R statistical software (version 3.2.2). Quantitative variables were described using mean and standard deviation (SD) for continuous variables and number and percentage for categorical variables. Comparisons between the two groups (fungal and non-fungal infection) were conducted using chi-squared test and Fisher's exact test. Univariate and multivariate analyses were conducted using linear regression analysis. Statistical significance was defined at $\alpha = 0.05$.

Results

Demographics (Table 1)

We found forty-three patients meeting the study criteria. The mean age was 39 ± 18.8 years and the study population was comprised of 24 males and 19 females. There were 41 cases of hematologic neoplasm.

Characteristic cutaneous lesions

The majority of patients had multiple skin lesions (67.4%). The most common morphology were nodular lesions (37.2%), and 58.1% was located on the lower extremities. Twenty-one (48.8%) of the patients had diagnosed FNP within 7.5 ± 8.7 days after presenting with skin lesions. Whereas, 22 (51.2%) had skin lesions approximately 9.0 ± 11.1 days after a diagnosis of FNP.

Dermatopathologic diagnosis

Fourteen (32.6%) of lesions were the result of infection, and 85.7% of these were fungal. Fourteen (32.6%) were the result of leukemia cutis.

Table 1. Basic Demographic, Clinical and Dermatopathologic Characteristics of the 43 Patients

Characteristic	No.	(%)
Age, mean (SD), y	39	(18.8)
Sex		
Male	24	55.8
Female	19	44.2
Underlying malignancy		
AML	21	48.8
Lymphoma	11	25.6
ALL	6	13.9
MDS/other hematologic	3	7
Solid	2	4.7
Number of skin lesions		
Single	14	32.6
Multiple	29	67.4
Morphology of skin lesions		
Nodule	16	37.2
Papule	12	27.9
Plaque	6	13.9
Blister	5	11.6
Ulcer	4	9.3
Other	8	18.6
Location of skin lesions		
Lower extremities	25	58.1
Upper extremities	20	46.5
Torso	20	46.5
Head and neck	11	25.6
Other	3	7
Dermatopathologic diagnosis		
Infections	14	32.6
Fungus	12	
Leukemia cutis	14	32.6
Drug reactions	6	13.9
Other/non-diagnosis	9	20.9

AML, acute myeloid leukemia; ALL, acute lymphoblastic leukemia; MDS, myelodysplastic syndrome

Predictive factors influencing common etiologies

Fungal infection

Twelve patients were diagnosed with having a fungal infection. 58.3% were male, and 75% were under the age of 40. All patients were in the high-risk group. 58.3% had been using antibacterial agents for more than seven days. The onset of skin lesions in patients with fungal infection occurring after FNP was statistically significantly higher than in the non-fungal infection group (Table 2).

In the multivariable analysis, which was controlled for age, onset of skin lesions, FNP group, and prolonged antibiotic use, an 80% reduced likelihood of fungal infection with patients who were over 40 years of age (OR, 0.20; 95% CI, 0.04-1.03; $P = 0.04$) was found. Patients who developed skin lesions after developing FNP were 8.13 times more likely to have fungal infections (OR, 8.13; 95% CI 1.4-47.17; $P = 0.009$) (Table 3).

Table 2. Characteristics of the Study Participants with Skin Fungal Infection Versus Non-Fungal Infections

Characteristic	No. (%)				P Value
	Fungal infection		Non-fungal infection		
Age, y					
<40	9	(75)	12	(38.7)	0.07 ^a
≥40	3	(25)	19	(61.3)	
Sex					
Male	7	(58.3)	17	(54.8)	1.00 ^a
Female	5	(41.7)	14	(45.2)	
Onset of skin lesions					
Before FNP	2	(16.7)	19	(61.3)	0.02 ^a
After FNP	10	(83.3)	12	(38.7)	
Number of skin lesions					
Single	5	(41.7)	9	(29)	0.48 ^b
Multiple	7	(58.3)	22	(71)	
Morphology of skin lesions					
Nodule	5	(41.7)	11	(64.5)	0.74 ^b
Location of skin lesions					
Lower extremities	7	(58.3)	18	(58.1)	1.00 ^a
Upper extremities	7	(58.3)	13	(41.9)	0.53 ^a
Torso	6	(50)	14	(45.2)	1.00 ^a
Head and neck	4	(33.3)	7	(22.6)	0.47 ^b
FNP group					
High-risk	12	(100)	23	(74.2)	0.08 ^b
Low-risk	0	0	8	(25.8)	
Antibiotics use >7 days					
No	5	(41.7)	23	(74.2)	0.07 ^b
Yes	7	(58.3)	8	(25.8)	

FNP, febrile neutropenia; ^a, chi-squared test; ^b, Fisher's exact test.

Leukemia cutis

Fourteen patients were diagnosed with leukemia cutis. Fifty-seven percent were male and presented with skin lesions before the onset of FNP. No factors predictive of leukemia cutis were found.

Dermatopathologic study and skin culture

Skin cultures were performed on 29 patients, and six were found to be positive for fungal infection. *Aspergillus spp.* was identified in two patients, *Candida spp.* in two, *Fusarium spp.* in one, and *Cladosporium spp.* in the other. Four of the six patients also tested positive for fungus in the pathological sections. Of the 23 patients found to be negative, surprisingly, five were found to be positive in the pathological sections.

Discussion

Typically, oncologic patients undergo multiple kinds of chemotherapy, and approximately 15% of patients developed FNP (Limvorapitak and Khawcharoenporn, 2015). These FNP patients must receive an empirical treatment with broad-spectrum antibiotics, antifungal drugs as well as leucocyte stimulating agents (Freifeld et al., 2011). When those of patients with FNP developed skin lesions, the differential diagnosis varies from patient's

Table 3. Multivariable Analysis of Factors Influencing Fungal Infection

Factor	OR (95% CI)		P Value (Wald's test)	P Value (LR-test)
	Crude	Adjusted ^a		
Age, y				
<40	1 [Reference]	1 [Reference]		
≥40	0.21 (0.05-0.94)	0.2 (0.04-1.03)	0.05	0.04
Onset of skin lesions				
Before FNP	1 [Reference]	1 [Reference]		
After FNP	7.92 (1.47-42.53)	8.13 (1.4-47.17)	0.02	0.009

FNP, febrile neutropenia; OR, odds ratio; ^a, model adjusted for age; the onset of skin lesions, FNP group, and antibiotic use.

disease, a complication of the treatment, etc. The infection including bacteria, virus, and fungus, the most important one of complications from chemotherapy, should be first considered because of an immunosuppressed status. This infection could be localized on the skin or systematized from internal organs (Mays et al., 2006). Furthermore, receiving many medications; therefore skin reaction and cutaneous drug eruptions could be occurring in febrile neutropenic patients (Mays and Cohen, 2006; Farmakiotis et al., 2013; Llamas-Velasco et al., 2013).

Proper diagnosis of cutaneous lesions in FNP is important. In our study, the most common etiologies of skin lesions were a fungal infection and leukemia cutis. These results align with a previous study which found the first three common causes of cutaneous lesions in FNP were an infection, leukemia cutis, and drug reactions, respectively (Farmakiotis et al., 2013).

Previous studies reported that an absolute neutrophil count of fewer than 100 cells/cu.mm, and greater than seven days of antibiotic use were risk factors for a fungal infection (Freifeld et al., 2011; Farmakiotis et al., 2013). The aforementioned factors were not found in this study possibly due to the small sample size; however, we found an analogous result with those who were diagnosed with fungal infections and with an absolute neutrophil count of fewer than 100 cells/cu.mm.

Additionally, we found two new predictors of a fungal infection. First, patients under the age of 40 had approximately a five times higher risk of fungal infection. In the past, advanced age patients with FNP receiving standard regimen were associated with increased mortality (Chindaprasirt et al., 2013). It was later almost always recommended a reduced- or palliative-dose chemotherapy in those with FNP who had significant co-morbidity (Brandwein et al., 2017; Iioka et al., 2016), thereby, theoretically developed less toxicity from the treatment, i.e., fewer FNP episodes and severity of neutropenia (Shayne et al., 2007; Xie et al., 2017). These possibly could result in decreasing risk of fungal infection in an older patient (Freifeld et al., 2011; Farmakiotis et al., 2013). Second, patients with skin lesions which occurred after diagnosed FNP had approximately an eight times higher risk of fungal infection. Patients who have had a neutropenic status might be at risk of fungal infection due to contracted circulating neutrophils and a lack of adequate

myeloid marrow reserve (West et al., 2017).

In contrast, leukemia cutis could have occurred any time before, during or after FNP and there were no predictive factors. To our knowledge, there were no studies on the correlation between onset to diagnosis of FNP and leukemia cutis. The large study from Korea reported 75 patients with leukemia cutis commonly presented with cutaneous nodules on the extremities, and the disease was associated with high mortality within a year (Kang et al., 2013). There was a difficulty in separating two significant conditions between leukemia cutis and fungal infection because the characteristic skin lesions of both entities were similar. Then, the skin biopsy must benefit tool for diagnosis in these patient setting.

The authors found the most common fungal organisms were *Aspergillus spp.*, *Candida spp.* and *Fusarium spp.* which was similar to findings in previous studies (Mays et al., 2006; Farmakiotis et al., 2013). Only 4 of 11 cases had concordant results between the pathologic diagnosis and tissue culture. A possible explanation for the discordance between the two test results might be that the tissue contained heterogeneity or nonviable fungi (Tarrand et al., 2003; Sangoi et al., 2009; Guarner and Brandt, 2011; Gonzalez Santiago et al., 2014). These discordant results lead to a recommendation that both a tissue biopsy for pathologic study and a skin culture be conducted to reach more definitive conclusions.

This study had some limitations. This was a retrospective of a small case from a single university hospital. Patients in the study were all non-transplant and had undergone histopathology during the FNP period.

In conclusion, cutaneous manifestations in patients with FNP were common in the multiple cutaneous nodules of the lower extremities. Fungal infection was a significant consideration, especially in patients who were young (under 40) and who had developed skin lesions after FNP. The authors recommend both a tissue biopsy for dermatopathologic study and culture to ensure a more efficient plan of treatment.

Funding sources

None.

Conflicts of interest

The authors have no conflicts of interest to declare.

Previous Presentation

This study was presented as an e-poster at the American Academy of Dermatology 74th Annual Meeting, March 4-8, 2016, Washington, D.C.

Acknowledgements

The authors are indebted to Ms. Jirawan Jayuphan, Epidemiology Unit, Faculty of Medicine, Prince of Songkla University (PSU) for providing help in statistical analysis, and we would like to thank Dr. Kathleen Nicoletti, PhD., Faculty of Liberal Arts, PSU for proofreading the article.

References

- Badr M, Hassan T, Sakr H, et al (2016). Chemotherapy-induced neutropenia among pediatric cancer patients in Egypt: Risks and consequences. *Mol Clin Oncol*, **5**, 300-6.
- Bodey GP (1994). Dermatologic manifestations of infections in neutropenic patients. *Infect Dis Clin North Am*, **8**, 655-75.
- Brandwein JM, Zhu N, Kumar R, et al (2017). Treatment of older patients with acute myeloid leukemia (AML): revised Canadian consensus guidelines. *Am J Blood Res*, **7**, 30-40.
- Chindaprasirt J, Wanitpongpun C, Limpawattana P, et al (2013). Mortality, length of stay, and cost associated with hospitalized adult cancer patients with febrile neutropenia. *Asian Pac J Cancer Prev*, **14**, 1115-9.
- Farmakiotis D, Ciurea AM, Cahuayme-Zuniga L, Kontoyiannis DP (2013). The diagnostic yield of skin biopsy in patients with leukemia and suspected infection. *J Infect*, **67**, 265-72.
- Freifeld AG, Bow EJ, Sepkowitz KA, et al (2011). Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. *Clin Infect Dis*, **52**, 427-31.
- Gonzalez Santiago TM, Pritt B, Gibson LE, Comfere NI (2014). Diagnosis of deep cutaneous fungal infections: correlation between skin tissue culture and histopathology. *J Am Acad Dermatol*, **71**, 293-301.
- Guarner J, Brandt ME (2011). Histopathologic diagnosis of fungal infections in the 21st century. *Clin Microbiol Rev*, **24**, 247-80.
- Iioka F, Izumi K, Kamoda Y, Akasaka T, Ohno H (2016). Outcomes of very elderly patients with aggressive B-cell non-Hodgkin lymphoma treated with reduced-dose chemotherapy. *Int J Clin Oncol*, **21**, 498-505.
- Jagarlamudi R, Kumar L, Kochupillai V, et al (2000). Infections in acute leukemia: an analysis of 240 febrile episodes. *Med Oncol*, **17**, 111-6.
- Kang YS, Kim HS, Park HJ, et al (2013). Clinical characteristics of 75 patients with leukemia cutis. *J Korean Med Sci*, **28**, 614-9.
- Karanwal AB, Parikh BJ, Goswami P, et al (2013). Review of clinical profile and bacterial spectrum and sensitivity patterns of pathogens in febrile neutropenic patients in hematological malignancies: A retrospective analysis from a single center. *Indian J Med Paediatr Oncol*, **34**, 85-8.
- Limvorapitak W, Khawcharoenporn T (2015). Incidence, risk factors, and outcomes of febrile neutropenia in Thai hematologic malignancy patients receiving chemotherapy: A 6-year retrospective cohort study. *Asian Pac J Cancer Prev*, **16**, 5949-50.
- Llamas-Velasco M, Garcia-Martin P, Sanchez-Perez J, Fraga J, Garcia-Diez A (2013). Sweet's syndrome with subcutaneous involvement associated with pegfilgrastim treatment: first reported case. *J Cutan Pathol*, **40**, 46-9.
- Mays SR, Bogle MA, Bodey GP (2006). Cutaneous fungal infections in the oncology patient: recognition and management. *Am J Clin Dermatol*, **7**, 31-43.
- Mays SR, Cohen PR (2006). Emerging dermatologic issues in the oncology patient. *Semin Cutan Med Surg*, **25**, 179-89.
- Roongpoovapatr P, Suankratay C (2010). Causative pathogens of fever in neutropenic patients at King Chulalongkorn Memorial Hospital. *J Med Assoc Thai*, **93**, 776-83.
- Sangoi AR, Rogers WM, Longacre TA, et al (2009). Challenges and pitfalls of morphologic identification of fungal infections in histologic and cytologic specimens: a ten-year retrospective review at a single institution. *Am J Clin Pathol*, **131**, 364-75.
- Shayne M, Culakova E, Poniewierski MS, et al (2007). Dose

- intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. *Cancer*, **110**, 1611-20.
- Tarrand JJ, Lichterfeld M, Warraich I, et al (2003). Diagnosis of invasive septate mold infections. A correlation of microbiological culture and histologic or cytologic examination. *Am J Clin Pathol*, **119**, 854-8.
- West KA, Gea-Banacloche J, Stroncek D, Kadri SS (2017). Granulocyte transfusions in the management of invasive fungal infections. *Br J Haematol*, **177**, 357-74.
- Xie X, Wu Y, Luo Sh, et al (2017). Efficacy and toxicity of low-dose versus conventional-dose chemotherapy for malignant tumors: a meta-analysis of 6 randomized controlled trials. *Asian Pac J Cancer Prev*, **18**, 479-84.